title: Venous thromboembolic disease in patients with haemophilia.
abstract: With the availability of efficient and safe clotting factor replacement therapy, elective total joint arthroplasty is increasingly performed in subjects with haemophilia suffering from chronic haemophilic arthropathy. Little has been published addressing the prevalence and the specific risk factors of thromboembolic complications and the role of thromboembolic prophylaxis in this specific population. While the risk of thrombosis in hemophilic patients following hip or knee arthroplasty is considered to be low and probably mitigated by the clotting factor deficiency, cases have been reported of pulmonary embolism and deep vein thrombosis in hemophilic patients. Although most guidelines advocate thromboembolic prophylaxis in the general population undergoing major orthopaedic surgery, no such standard of care is in place for hemophilic patients. This paper discusses the scope of the problem of venous thromboembolism in patients with haemophilia undergoing major orthopaedic surgery and reviews the published approaches to the use of prophylactic anticoagulation in this setting.
authors.affiliation: Division of Haematology, Haemostasis and Thrombosis Unit, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium. cedric.hermans@uclouvain.be
authors.forename: Cedric
authors.initials: C
authors.lastname: Hermans
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D003029:Coagulants / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006467:Hemophilia A / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D019637:Orthopedic Procedures / Q000009:adverse effects*; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome; D054556:Venous Thromboembolism / Q000097:blood / Q000209:etiology / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D003029:Coagulants; D005343:Fibrinolytic Agents